ClinicalTrials.gg
CompletedNCT03872401VESALIUS-CVUpdated Jun 25, 2026Results posted

Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke

A Phase 3 interventional study of Evolocumab and Placebo in Coronary Heart Disease (CHD), sponsored by Amgen. Completed at 852 sites in 33 countries. Open to participants aged 50 Years to 79 Years. Per ClinicalTrials.gov, last updated 2026-06-25.

Sponsored by Amgen · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
12,301
Allocation
Randomized
Ages
50 Years to 79 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 274 studies in Coronary Disease with a site in United States — 12 open to participants now, 23 under way, 2 of them phase 3. Coronary Disease · United States.

Enrollment
6th of 184
12,301 · median 200
Started
2019
with 8 others
Phase 3
35 of 274
2 open now
Registered
242nd of 274
by date

Among the 274 studies in Coronary Disease with a site in United States, this one is the 6th largest by enrollment of the 184 interventional ones that give a count, is one of 9 that started in 2019, is one of 35 in phase 3, and was the 242nd registered.

Coronary Disease

1,521 studies on the registry are indexed under Coronary Disease; 167 are open to participants now.

Browse Coronary Disease studies →

Open to participants now

12 of the 274 studies in Coronary Disease with a site in United States are open now. Recruiting first, the newest first:

7 more — sign in →

All 12 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 105 Coronary Disease studies recruiting now, 63 (60%) set no upper age limit and 19 (18%) stop at 75 or younger; 8 take children under 18; 10 take healthy volunteers.

This study: 50 Years to 79 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 274 studies in Coronary Disease with a site in United States, or all of them as a file.
02

Study summary

This study will assess the effect of lowering low-density lipoprotein cholesterol (LDL-C) with evolocumab on major cardiovascular events in adults without a prior myocardial infarction (MI) or stroke who are at high risk of a cardiovascular event.

03

Conditions studied

  • Coronary Heart Disease (CHD)

Browse trials for

Keywords

  • High Cardiovascular Risk
  • No prior Myocardial Infarction stroke
  • >= 50 years of age (men)
  • >= 55 years of age (women)
  • lipid-lowering therapy
04

Who can participate

Ages eligible
50 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age: Adult participants ≥ 50 (men) or ≥ 55 (women) to ˂ 80 years of age (either sex) and meeting lipid criteria.
  • Lipid Criteria: Low-density lipoprotein cholesterol (LDL-C) ≥ 90 mg/dL (≥ 2.3 mmol/L) or non high-density lipoprotein cholesterol (non-HDL)-C ≥ 120 mg/dL (≥ 3.1 mmol/L), or apolipoprotein B ≥ 80 mg/dL (≥ 1.56 µmol/L).

    3.Diagnostic evidence of at least one of the following (A-D) at screening:

A.Significant coronary artery disease (CAD) meeting at least 1 of the following criteria:

  • History of coronary revascularization with multi-vessel coronary disease as evidenced by any of the following:

    1. percutaneous coronary intervention (PCI) of 2 or more vessels, including branch arteries,
    2. PCI or coronary artery bypass grafting (CABG) with residual 50% stenosis in a separate, unrevascularized vessel, or
    3. multi-vessel CABG 5 years or more prior to screening.
  • Significant coronary disease without prior revascularization as evidenced by either a ≥70% stenosis of at least 1 coronary artery, ≥50% stenosis of 2 or more coronary arteries, or ≥50% stenosis of the left main coronary artery.
  • known coronary artery calcium score ≥100 in participants without a coronary artery revascularization prior to randomization.

B. Significant atherosclerotic cerebrovascular disease meeting at least 1 of the following criteria:

  • prior with ≥50% carotid stenosis.
  • internal or external carotid artery stenosis of ≥70% or 2 or more ≥50% stenoses.
  • prior internal or external carotid artery revascularization.

C. Significant peripheral arterial disease meeting at least 1 of the following criteria:

  • ≥50% stenosis in a limb artery.
  • history of abdominal aorta treatment (percutaneous and surgical) due to atherosclerotic disease.
  • ankle brachial index (ABI) \<0.85.

D. Diabetes mellitus with at least 1 of the following:

  • known microvascular disease, defined by diabetic nephropathy or treated retinopathy. Diabetic nephropathy defined as persistent microalbuminuria (urinary albumin to creatinine ratio ≥30mg/g) and/or persistent estimated (eGFR) \<60 mL/min/1.73 m\^2 that is not reversible due to an acute illness.
  • chronic daily treatment with an intermediate or long-acting insulin.
  • diabetes diagnosis ≥10 years ago.

    •At least 1 of the following 1 high-risk criteria (most recent lab values within 6 months prior to screening, as applicable):

  • Polyvascular disease, defined as coronary, carotid, or peripheral artery stenosis ≥50% in a second distinct vascular location in a participant with coronary, cerebral or peripheral arterial disease (A, B, or C above).
  • Presence of either diabetes mellitus or metabolic syndrome in a participant with coronary, cerebral, or peripheral artery disease (A, B, or C above).
  • At least 1 coronary, carotid, or peripheral artery residual stenosis of ≥50% in a participant with diabetes meeting inclusion criterion (D above).
  • LDL-C ≥130 mg/dL (≥3.36 mmol/L), OR non-HDL-C ≥160 mg/dL (≥4.14 mmol/L), OR apolipoprotein B ≥120 mg/dL (2.3 µmol/L) if available.
  • Lipoprotein (a) >125 nmol/L (50 mg/dL).
  • Known familial hypercholesterolemia.
  • Family history of premature coronary artery disease defined as an MI or CABG in the participant's father or brother at age \<55 years or an MI or CABG in the participant's mother or sister at age \<60 years.
  • High sensitive c-reactive protein (hsCRP) ≥3.0 mg/L in the absence of an acute illness.
  • Current tobacco use.

    -≥65 years of age.

  • Menopause before 40 years of age.
  • eGFR 15 to \<45 mL/min/1.73 m\^2.
  • Coronary artery calcification score ≥300 in a participant without a coronary revascularization prior to randomization.

Exclusion criteria

Exclusion criteria

  • MI or stroke prior to randomization.
  • CABG ˂ 3 months prior to screening.
  • ˂ 15 mL/min/1.73 m\^2.
  • Uncontrolled or recurrent ventricular tachycardia in the absence of an implantable-cardioverter defibrillator.
  • Atrial fibrillation or atrial flutter not on anticoagulation therapy (vitamin K antagonist, heparin, low molecular weight heparin, fondaparinux,or non-Vitamin K antagonist oral anticoagulant).
  • Triglycerides ≥ 500 mg/dL (5.7 mmol/L) measured up to 3 months prior to screening. The most recent results must be used.
  • Last measured left-ventricular ˂ 30% or (NYHA) Functional Class III/IV.
  • Planned arterial revascularization.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
12,301 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Participants will receive placebo subcutaneous injection once every 2 weeks (Q2W).

    Drug: Placebo

  • Experimental
    Evolocumab 140 mg Q2W

    Participants will receive 140 mg evolocumab by subcutaneous injection Q2W.

    Drug: Evolocumab

Interventions

  • Administered subcutaneously using an autoinjector pen.

    Also known as: AMG 145, Repatha

  • DrugPlacebo

    Administered subcutaneously using an autoinjector pen.

06

What researchers measure

Primary outcomes

  1. Number of Participants Who Experienced Coronary Heart Disease (CHD) Death, Myocardial Infarction (MI), or Ischemic Stroke, Whichever Occurred First

    All deaths and individual components were adjudicated by an independent external clinical events committee (CEC), using standardized definitions. The number of participants who experienced CHD death, MI, or ischemic stroke, whichever occurred first, among participants at high cardiovascular risk without prior MI or stroke and were receiving optimized lipid lowering therapy was analyzed.

    Time frame: From enrollment to last confirmed survival status date; median (min, max) time on trial was 55.2 (0.0, 72.7) months

  2. Number of Participants Who Experienced CHD Death, MI, Ischemic Stroke, or Any Ischemia-driven Arterial Revascularization, Whichever Occurred First

    All deaths and individual components were adjudicated by an independent external CEC, using standardized definitions. The number of participants who experienced CHD death, MI, ischemic stroke, or any ischemia-driven arterial revascularization, whichever occurred first, among participants at high cardiovascular risk without prior MI or stroke and were receiving optimized lipid lowering therapy was analyzed.

    Time frame: From enrollment to last confirmed survival status date; median (min, max) time on trial was 55.2 (0.0, 72.7) months

Secondary outcomes

  1. Number of Participants Who Experienced MI, Ischemic Stroke, or Any Ischemia-driven Arterial Revascularization

    All deaths and individual components were adjudicated by an independent external CEC, using standardized definitions. The number of participants who experienced MI, ischemic stroke, or any ischemia-driven arterial revascularization, among participants at high cardiovascular risk without prior MI or stroke and were receiving optimized lipid lowering therapy was analyzed.

    Time frame: From enrollment to last confirmed survival status date; median (min, max) time on trial was 55.2 (0.0, 72.7) months

  2. Number of Participants Who Experienced CHD Death, MI, or Any Ischemia-driven Arterial Revascularization

    All deaths and individual components were adjudicated by an independent external CEC, using standardized definitions. The number of participants who experienced CHD death, MI, or any ischemia-driven arterial revascularization, among participants at high cardiovascular risk without prior MI or stroke and were receiving optimized lipid lowering therapy was analyzed.

    Time frame: From enrollment to last confirmed survival status date; median (min, max) time on trial was 55.2 (0.0, 72.7) months

  3. Number of Participants Who Experienced Cardiovascular Death, MI, or Ischemic Stroke

    All deaths and individual components were adjudicated by an independent external CEC, using standardized definitions. The number of participants who experienced cardiovascular death, MI, or ischemic stroke, among participants at high cardiovascular risk without prior MI or stroke and were receiving optimized lipid lowering therapy was analyzed.

    Time frame: From enrollment to last confirmed survival status date; median (min, max) time on trial was 55.2 (0.0, 72.7) months

  4. Number of Participants Who Experienced CHD Death or MI

    All deaths and individual components were adjudicated by an independent external CEC, using standardized definitions. The number of participants who experienced CHD death or MI, among participants at high cardiovascular risk without prior MI or stroke and were receiving optimized lipid lowering therapy was analyzed.

    Time frame: From enrollment to last confirmed survival status date; median (min, max) time on trial was 55.2 (0.0, 72.7) months

  5. Number of Participants Who Experienced MI

    All deaths and individual components were adjudicated by an independent external CEC, using standardized definitions. The number of participants who experienced MI, among participants at high cardiovascular risk without prior MI or stroke and were receiving optimized lipid lowering therapy was analyzed.

    Time frame: From enrollment to last confirmed survival status date; median (min, max) time on trial was 55.2 (0.0, 72.7) months

  6. Number of Participants Who Experienced Any Ischemia-driven Arterial Revascularization

    All deaths and individual components were adjudicated by an independent external CEC, using standardized definitions. The number of participants who experienced ischemia-driven arterial revascularization, among participants at high cardiovascular risk without prior MI or stroke and were receiving optimized lipid lowering therapy was analyzed.

    Time frame: From enrollment to last confirmed survival status date; median (min, max) time on trial was 55.2 (0.0, 72.7) months

  7. Number of Participants Who Experienced CHD Death

    All deaths and individual components were adjudicated by an independent external CEC, using standardized definitions. The number of participants who experienced CHD death, among participants at high cardiovascular risk without prior MI or stroke and were receiving optimized lipid lowering therapy was analyzed.

    Time frame: From enrollment to last confirmed survival status date; median (min, max) time on trial was 55.2 (0.0, 72.7) months

  8. Number of Participants Who Experienced Cardiovascular Death

    All deaths and individual components were adjudicated by an independent external CEC, using standardized definitions. The number of participants who experienced cardiovascular death, among participants at high cardiovascular risk without prior MI or stroke and were receiving optimized lipid lowering therapy was analyzed.

    Time frame: From enrollment to last confirmed survival status date; median (min, max) time on trial was 55.2 (0.0, 72.7) months

  9. Number of Participants Who Died Due to Any Cause

    All deaths and individual components were adjudicated by an independent external CEC, using standardized definitions. The number of participants who died due to any cause, among participants at high cardiovascular risk without prior MI or stroke and were receiving optimized lipid lowering therapy was analyzed.

    Time frame: From enrollment to last confirmed survival status date; median (min, max) time on trial was 55.2 (0.0, 72.7) months

  10. Number of Participants Who Experienced Ischemic Stroke

    All deaths and individual components were adjudicated by an independent external CEC, using standardized definitions. The number of participants who experienced ischemic stroke, among participants at high cardiovascular risk without prior MI or stroke and were receiving optimized lipid lowering therapy was analyzed.

    Time frame: From enrollment to last confirmed survival status date; median (min, max) time on trial was 55.2 (0.0, 72.7) months

07

Results

Posted Jun 25, 2026
Limitations and caveats
44 participants enrolled were excluded from all efficacy and safety analysis, due to site-wide serious breaches and good clinical practice (GCP) violations.

Participant flow

Participants were enrolled at 745 research centers in North America, Europe, Asia Pacific, and Latin America between June 2019 and July 2025.

Participant flow — Overall Study
MilestonePlacebo Q2WEvolocumab 140 mg Q2W
Started61286129
Completed59855999
Not completed143130
Withdrew: Withdrawal of consent from trial10493
Withdrew: Lost to follow-up2419
Withdrew: Administrative reasons1516
Withdrew: Various reasons02

Outcome measures

PrimaryNumber of Participants Who Experienced Coronary Heart Disease (CHD) Death, Myocardial Infarction (MI), or Ischemic Stroke, Whichever Occurred First

All deaths and individual components were adjudicated by an independent external clinical events committee (CEC), using standardized definitions. The number of participants who experienced CHD death, MI, or ischemic stroke, whichever occurred first, among participants at high cardiovascular risk without prior MI or stroke and were receiving optimized lipid lowering therapy was analyzed.

Time frame:
From enrollment to last confirmed survival status date; median (min, max) time on trial was 55.2 (0.0, 72.7) months
Reported as:
Count of participants · Participants
Number of Participants Who Experienced Coronary Heart Disease (CHD) Death, Myocardial Infarction (MI), or Ischemic Stroke, Whichever Occurred First
ParticipantsPlacebo Q2WEvolocumab 140 mg Q2W
Number of Participants Who Experienced Coronary Heart Disease (CHD) Death, Myocardial Infarction (MI), or Ischemic Stroke, Whichever Occurred First443336
Statistical analysis
  • Placebo Q2W vs Evolocumab 140 mg Q2W · Log Rank · p = < 0.001 · Hazard ratio (hr): 0.75 · 95% CI 0.65 to 0.86Based on a Cox model stratified by the randomization stratification factors collected via IVRS/IWRS.
PrimaryNumber of Participants Who Experienced CHD Death, MI, Ischemic Stroke, or Any Ischemia-driven Arterial Revascularization, Whichever Occurred First

All deaths and individual components were adjudicated by an independent external CEC, using standardized definitions. The number of participants who experienced CHD death, MI, ischemic stroke, or any ischemia-driven arterial revascularization, whichever occurred first, among participants at high cardiovascular risk without prior MI or stroke and were receiving optimized lipid lowering therapy was analyzed.

Time frame:
From enrollment to last confirmed survival status date; median (min, max) time on trial was 55.2 (0.0, 72.7) months
Reported as:
Count of participants · Participants
Number of Participants Who Experienced CHD Death, MI, Ischemic Stroke, or Any Ischemia-driven Arterial Revascularization, Whichever Occurred First
ParticipantsPlacebo Q2WEvolocumab 140 mg Q2W
Number of Participants Who Experienced CHD Death, MI, Ischemic Stroke, or Any Ischemia-driven Arterial Revascularization, Whichever Occurred First907747
Statistical analysis
  • Placebo Q2W vs Evolocumab 140 mg Q2W · Log Rank · p = < 0.001 · Hazard ratio (hr): 0.81 · 95% CI 0.73 to 0.89Based on a Cox model stratified by the randomization stratification factors collected via IVRS/IWRS.
SecondaryNumber of Participants Who Experienced MI, Ischemic Stroke, or Any Ischemia-driven Arterial Revascularization

All deaths and individual components were adjudicated by an independent external CEC, using standardized definitions. The number of participants who experienced MI, ischemic stroke, or any ischemia-driven arterial revascularization, among participants at high cardiovascular risk without prior MI or stroke and were receiving optimized lipid lowering therapy was analyzed.

Time frame:
From enrollment to last confirmed survival status date; median (min, max) time on trial was 55.2 (0.0, 72.7) months
Reported as:
Count of participants · Participants
Number of Participants Who Experienced MI, Ischemic Stroke, or Any Ischemia-driven Arterial Revascularization
ParticipantsPlacebo Q2WEvolocumab 140 mg Q2W
Number of Participants Who Experienced MI, Ischemic Stroke, or Any Ischemia-driven Arterial Revascularization834674
Statistical analysis
  • Placebo Q2W vs Evolocumab 140 mg Q2W · Log Rank · p = < 0.001 · Hazard ratio (hr): 0.79 · 95% CI 0.72 to 0.88Based on a Cox model stratified by the randomization stratification factors collected via IVRS/IWRS.
SecondaryNumber of Participants Who Experienced CHD Death, MI, or Any Ischemia-driven Arterial Revascularization

All deaths and individual components were adjudicated by an independent external CEC, using standardized definitions. The number of participants who experienced CHD death, MI, or any ischemia-driven arterial revascularization, among participants at high cardiovascular risk without prior MI or stroke and were receiving optimized lipid lowering therapy was analyzed.

Time frame:
From enrollment to last confirmed survival status date; median (min, max) time on trial was 55.2 (0.0, 72.7) months
Reported as:
Count of participants · Participants
Number of Participants Who Experienced CHD Death, MI, or Any Ischemia-driven Arterial Revascularization
ParticipantsPlacebo Q2WEvolocumab 140 mg Q2W
Number of Participants Who Experienced CHD Death, MI, or Any Ischemia-driven Arterial Revascularization819664
Statistical analysis
  • Placebo Q2W vs Evolocumab 140 mg Q2W · Log Rank · p = < 0.001 · Hazard ratio (hr): 0.79 · 95% CI 0.72 to 0.88Based on a Cox model stratified by the randomization stratification factors collected via IVRS/IWRS.
SecondaryNumber of Participants Who Experienced Cardiovascular Death, MI, or Ischemic Stroke

All deaths and individual components were adjudicated by an independent external CEC, using standardized definitions. The number of participants who experienced cardiovascular death, MI, or ischemic stroke, among participants at high cardiovascular risk without prior MI or stroke and were receiving optimized lipid lowering therapy was analyzed.

Time frame:
From enrollment to last confirmed survival status date; median (min, max) time on trial was 55.2 (0.0, 72.7) months
Reported as:
Count of participants · Participants
Number of Participants Who Experienced Cardiovascular Death, MI, or Ischemic Stroke
ParticipantsPlacebo Q2WEvolocumab 140 mg Q2W
Number of Participants Who Experienced Cardiovascular Death, MI, or Ischemic Stroke503374
Statistical analysis
  • Placebo Q2W vs Evolocumab 140 mg Q2W · Log Rank · p = < 0.001 · Hazard ratio (hr): 0.73 · 95% CI 0.64 to 0.84Based on a Cox model stratified by the randomization stratification factors collected via IVRS/IWRS.
SecondaryNumber of Participants Who Experienced CHD Death or MI

All deaths and individual components were adjudicated by an independent external CEC, using standardized definitions. The number of participants who experienced CHD death or MI, among participants at high cardiovascular risk without prior MI or stroke and were receiving optimized lipid lowering therapy was analyzed.

Time frame:
From enrollment to last confirmed survival status date; median (min, max) time on trial was 55.2 (0.0, 72.7) months
Reported as:
Count of participants · Participants
Number of Participants Who Experienced CHD Death or MI
ParticipantsPlacebo Q2WEvolocumab 140 mg Q2W
Number of Participants Who Experienced CHD Death or MI313232
Statistical analysis
  • Placebo Q2W vs Evolocumab 140 mg Q2W · Log Rank · p = < 0.001 · Hazard ratio (hr): 0.73 · 95% CI 0.62 to 0.87Based on a Cox model stratified by the randomization stratification factors collected via IVRS/IWRS.
SecondaryNumber of Participants Who Experienced MI

All deaths and individual components were adjudicated by an independent external CEC, using standardized definitions. The number of participants who experienced MI, among participants at high cardiovascular risk without prior MI or stroke and were receiving optimized lipid lowering therapy was analyzed.

Time frame:
From enrollment to last confirmed survival status date; median (min, max) time on trial was 55.2 (0.0, 72.7) months
Reported as:
Count of participants · Participants
Number of Participants Who Experienced MI
ParticipantsPlacebo Q2WEvolocumab 140 mg Q2W
Number of Participants Who Experienced MI229149
Statistical analysis
  • Placebo Q2W vs Evolocumab 140 mg Q2W · Log Rank · p = < 0.001 · Hazard ratio (hr): 0.64 · 95% CI 0.52 to 0.79Based on a Cox model stratified by the randomization stratification factors collected via IVRS/IWRS.
SecondaryNumber of Participants Who Experienced Any Ischemia-driven Arterial Revascularization

All deaths and individual components were adjudicated by an independent external CEC, using standardized definitions. The number of participants who experienced ischemia-driven arterial revascularization, among participants at high cardiovascular risk without prior MI or stroke and were receiving optimized lipid lowering therapy was analyzed.

Time frame:
From enrollment to last confirmed survival status date; median (min, max) time on trial was 55.2 (0.0, 72.7) months
Reported as:
Count of participants · Participants
Number of Participants Who Experienced Any Ischemia-driven Arterial Revascularization
ParticipantsPlacebo Q2WEvolocumab 140 mg Q2W
Number of Participants Who Experienced Any Ischemia-driven Arterial Revascularization699561
Statistical analysis
  • Placebo Q2W vs Evolocumab 140 mg Q2W · Log Rank · p = < 0.001 · Hazard ratio (hr): 0.79 · 95% CI 0.70 to 0.88Based on a Cox model stratified by the randomization stratification factors collected via IVRS/IWRS.
SecondaryNumber of Participants Who Experienced CHD Death

All deaths and individual components were adjudicated by an independent external CEC, using standardized definitions. The number of participants who experienced CHD death, among participants at high cardiovascular risk without prior MI or stroke and were receiving optimized lipid lowering therapy was analyzed.

Time frame:
From enrollment to last confirmed survival status date; median (min, max) time on trial was 55.2 (0.0, 72.7) months
Reported as:
Count of participants · Participants
Number of Participants Who Experienced CHD Death
ParticipantsPlacebo Q2WEvolocumab 140 mg Q2W
Number of Participants Who Experienced CHD Death117105
Statistical analysis
  • Placebo Q2W vs Evolocumab 140 mg Q2W · Log Rank · p = = 0.39 · Hazard ratio (hr): 0.89 · 95% CI 0.68 to 1.16Based on a Cox model stratified by the randomization stratification factors collected via IVRS/IWRS.
SecondaryNumber of Participants Who Experienced Cardiovascular Death

All deaths and individual components were adjudicated by an independent external CEC, using standardized definitions. The number of participants who experienced cardiovascular death, among participants at high cardiovascular risk without prior MI or stroke and were receiving optimized lipid lowering therapy was analyzed.

Time frame:
From enrollment to last confirmed survival status date; median (min, max) time on trial was 55.2 (0.0, 72.7) months
Reported as:
Count of participants · Participants
Number of Participants Who Experienced Cardiovascular Death
ParticipantsPlacebo Q2WEvolocumab 140 mg Q2W
Number of Participants Who Experienced Cardiovascular Death195156
Statistical analysis
  • Placebo Q2W vs Evolocumab 140 mg Q2W · Log Rank · p = = 0.031 · Hazard ratio (hr): 0.79 · 95% CI 0.64 to 0.98Based on a Cox model stratified by the randomization stratification factors collected via IVRS/IWRS.
SecondaryNumber of Participants Who Died Due to Any Cause

All deaths and individual components were adjudicated by an independent external CEC, using standardized definitions. The number of participants who died due to any cause, among participants at high cardiovascular risk without prior MI or stroke and were receiving optimized lipid lowering therapy was analyzed.

Time frame:
From enrollment to last confirmed survival status date; median (min, max) time on trial was 55.2 (0.0, 72.7) months
Reported as:
Count of participants · Participants
Number of Participants Who Died Due to Any Cause
ParticipantsPlacebo Q2WEvolocumab 140 mg Q2W
Number of Participants Who Died Due to Any Cause539434
Statistical analysis
  • Placebo Q2W vs Evolocumab 140 mg Q2W · Log Rank · p = < 0.001 · Hazard ratio (hr): 0.80 · 95% CI 0.70 to 0.91Based on a Cox model stratified by the randomization stratification factors collected via IVRS/IWRS.
SecondaryNumber of Participants Who Experienced Ischemic Stroke

All deaths and individual components were adjudicated by an independent external CEC, using standardized definitions. The number of participants who experienced ischemic stroke, among participants at high cardiovascular risk without prior MI or stroke and were receiving optimized lipid lowering therapy was analyzed.

Time frame:
From enrollment to last confirmed survival status date; median (min, max) time on trial was 55.2 (0.0, 72.7) months
Reported as:
Count of participants · Participants
Number of Participants Who Experienced Ischemic Stroke
ParticipantsPlacebo Q2WEvolocumab 140 mg Q2W
Number of Participants Who Experienced Ischemic Stroke144115
Statistical analysis
  • Placebo Q2W vs Evolocumab 140 mg Q2W · Log Rank · p = = 0.062 · Hazard ratio (hr): 0.79 · 95% CI 0.62 to 1.01Based on a Cox model stratified by the randomization stratification factors collected via IVRS/IWRS.

Adverse events

Collected over All-cause mortality: From enrollment to last confirmed survival status date; median (min, max) time on trial was 55.2 (0.0, 72.7) months. Serious adverse events (AEs) and other AEs: From first dose of trial drug to last dose + 30 days or end of trial; median (min, max) time on trial was 51.5 (0.0, 72.4) months.. Non-serious events are listed at a 0.1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo Q2W539/6,128 (8.8%)1,772/6,122 (28.9%)35/6,122 (0.6%)
Evolocumab 140 mg Q2W434/6,129 (7.1%)1,726/6,125 (28.2%)55/6,125 (0.9%)
Most frequent serious events
Showing 10 of 1,239
Most frequent serious events
EventPlacebo Q2WEvolocumab 140 mg Q2W
Angina unstableCardiac disorders96/6122102/6125
Coronary artery diseaseCardiac disorders101/612281/6125
Angina pectorisCardiac disorders100/612283/6125
OsteoarthritisMusculoskeletal and connective tissue disorders69/612296/6125
COVID-19 pneumoniaInfections and infestations86/612282/6125
Peripheral arterial occlusive diseaseVascular disorders86/612275/6125
Atrial fibrillationCardiac disorders76/612268/6125
PneumoniaInfections and infestations64/612272/6125
Cardiac failureCardiac disorders63/612243/6125
HypertensionVascular disorders41/612223/6125
Most frequent other events
Most frequent other events
EventPlacebo Q2WEvolocumab 140 mg Q2W
MyalgiaMusculoskeletal and connective tissue disorders18/612230/6125
HeadacheNervous system disorders6/612211/6125
RashSkin and subcutaneous tissue disorders2/61229/6125
ArthralgiaMusculoskeletal and connective tissue disorders8/61227/6125
NauseaGastrointestinal disorders3/61228/6125

Baseline characteristics

FAS included all randomized participants. All participants were analyzed according to their randomized treatment assignment.

Age, Continuous
Age, Continuous(years)Placebo Q2WEvolocumab 140 mg Q2WTotal
Mean65.3 ± 6.965.5 ± 6.965.4 ± 6.9
Sex: Female, Male
Sex: Female, Male(Participants)Placebo Q2WEvolocumab 140 mg Q2WTotal
Female259526195214
Male353335107043
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Placebo Q2WEvolocumab 140 mg Q2WTotal
Hispanic or Latino101610172033
Not Hispanic or Latino5110511010220
Unknown or Not Reported224
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Placebo Q2WEvolocumab 140 mg Q2WTotal
American Indian or Alaska Native282553
Asian243245488
Native Hawaiian or Other Pacific Islander235
Black or African American123115238
White5693570811401
More than one race437
Unknown or Not Reported353065
08

Study locations

852 sites
  • North Alabama Research Center LLC
    Athens, Alabama 35611, United States
  • Cardiovascular Associates
    Birmingham, Alabama 35243, United States
  • Heart Center Research LLC
    Huntsville, Alabama 35801, United States
  • Mobile Heart Specialists PC
    Mobile, Alabama 36608, United States
  • Arkansas Cardiology
    Little Rock, Arkansas 72205, United States
  • Central Arkansas Veterans Healthcare System
    Little Rock, Arkansas 72205, United States
  • Cardiovascular Research Foundation of Southern California
    Beverly Hills, California 90210, United States
  • Westside Medical Associates of Los Angeles
    Beverly Hills, California 90211, United States
  • West Coast Research LLC
    Dublin, California 94568, United States
  • Desert Oasis Healthcare Medical Group
    Palm Springs, California 92262, United States
  • Covigilant Research, LLC
    Riverside, California 92506, United States
  • Sierra Clinical Research
    Roseville, California 95661, United States
  • Center for Clinical Trials of Sacramento Inc
    Sacramento, California 95823, United States
  • Harbor University of California Los Angeles Medical Center
    Torrance, California 90502, United States
  • Optumcare Colorado Springs LLC
    Colorado Springs, Colorado 80906, United States
  • University of Colorado Memorial Health System
    Colorado Springs, Colorado 80909, United States
  • New West Physicians
    Golden, Colorado 80401, United States
  • South Denver Cardiology Associates
    Littleton, Colorado 80120, United States
  • Cardiology Associates of Fairfield County, PC
    Stamford, Connecticut 06905, United States
  • Excel Medical Clinical Trials
    Boca Raton, Florida 33434, United States
  • Bay Area Cardiology
    Brandon, Florida 33511, United States
  • Nature Coast Clinical Research LLC
    Crystal River, Florida 34429, United States
  • Daytona Heart Group
    Daytona Beach, Florida 32114, United States
  • Cardiology Research Associates
    Daytona Beach, Florida 32117, United States
  • Complete Health Research
    DeLand, Florida 32720, United States
  • Cohen Medical Associates PA
    Delray Beach, Florida 33446, United States
  • Jellinger and Lerman MD PA dba The Center for Diabetes and Endocrine Care
    Fort Lauderdale, Florida 33312, United States
  • George E Platt MD
    Green Cove Springs, Florida 32043, United States
  • Research Physicians Network Alliance
    Hollywood, Florida 33021, United States
  • University of Florida and Shands Hospital
    Jacksonville, Florida 32209, United States
  • Jacksonville Center for Clinical Research
    Jacksonville, Florida 32216, United States
  • First Coast Cardiovascular Institute PA
    Jacksonville, Florida 32256, United States
  • Baptist Health Research Institute
    Jacksonville Beach, Florida 32250, United States
  • Gad Research Center
    Miami, Florida 33155, United States
  • Cardiovascular Research Center of South Florida
    Miami, Florida 33173, United States
  • Ocala Research Institute, Inc
    Ocala, Florida 34471, United States
  • Cardiology Consultants
    Pensacola, Florida 32501, United States
  • Charlotte Heart Group Research Center
    Port Charlotte, Florida 33952, United States
  • Intercoastal Medical Group
    Sarasota, Florida 34232, United States
  • Cardiovascular Center of Sarasota
    Sarasota, Florida 34239, United States
  • Florida Cardiology Group
    Winter Park, Florida 32792, United States
  • The Florida Lipid Institute
    Winter Park, Florida 32792, United States
  • NSC Research
    Johns Creek, Georgia 30024, United States
  • Kootenai Heart Clinics, LLC
    Coeur d'Alene, Idaho 83814, United States
  • Northwest Heart Clinical Research LLC
    Arlington Heights, Illinois 60005, United States
  • Deaconess Clinic
    Evansville, Indiana 47713, United States
  • LaPorte County Institute for Clinical Research
    Michigan City, Indiana 46360, United States
  • Midwest Cardiovascular Research Foundation
    Davenport, Iowa 52801, United States
  • The University of Iowa College of Public Health
    Iowa City, Iowa 52242, United States
  • MercyOne Iowa Heart Center
    West Des Moines, Iowa 50266, United States
  • The University of Kansas Medical Center
    Kansas City, Kansas 66160-7601, United States
  • Saint Elizabeth Covington
    Covington, Kentucky 41011, United States
  • The Research Group of Lexington LLC
    Lexington, Kentucky 40503, United States
  • Alexandria Cardiology Clinic
    Alexandria, Louisiana 71301, United States
  • Grace Research LLC
    Bossier City, Louisiana 71111, United States
  • Horizon Research Group of Opelousas LLC
    Eunice, Louisiana 70535, United States
  • Louisiana Heart Center
    Hammond, Louisiana 70403, United States
  • Barnum Medical Research
    Natchitoches, Louisiana 71457, United States
  • Grace Research LLC
    Shreveport, Louisiana 71105, United States
  • Louisiana Heart Center
    Slidell, Louisiana 70458, United States
  • Northern Light Eastern Maine Medical Center
    Bangor, Maine 04401, United States
  • Southern Maine Health Care
    Biddeford, Maine 04005, United States
  • Maryland Cardiovascular Specialists
    Baltimore, Maryland 21229, United States
  • Metropolitan Cardiovascular Consultants LLC
    Beltsville, Maryland 20705, United States
  • TidalHealth Peninsula Regional, Inc
    Salisbury, Maryland 21804, United States
  • Brigham and Womens Hospital
    Boston, Massachusetts 02215, United States
  • Charles River Medical Associates
    Framingham, Massachusetts 01701, United States
  • East Mountain Medical Associates, PC
    Great Barrington, Massachusetts 01230, United States
  • Baystate Health Center
    Springfield, Massachusetts 01199, United States
  • Ahmed Arif Medical Research Center LLC
    Flint, Michigan 48504, United States
  • Healthy Heart Cardiology
    Grand Rapids, Michigan 49546, United States
  • Rajendra H Mehta, MD, PC
    Jackson, Michigan 49201, United States
  • Munson Medical Center
    Traverse City, Michigan 49684, United States
  • Saint Marys Medical Center
    Duluth, Minnesota 55805, United States
  • Minneapolis Heart Institute Foundation
    Minneapolis, Minnesota 55407, United States
  • Saint Cloud Hospital
    Saint Cloud, Minnesota 56303, United States
  • HealthEast Medical Research Institute
    Saint Paul, Minnesota 55102, United States
  • Kansas City Veterans Affairs Medical Center
    Kansas City, Missouri 64128, United States
  • Mercy Research
    St Louis, Missouri 63141, United States
  • Great Falls Clinic LLP
    Great Falls, Montana 59405, United States
  • Bryan Heart
    Lincoln, Nebraska 68506, United States
  • Nebraska Western Iowa Health Care System
    Omaha, Nebraska 68105, United States
  • Palm Research Center Inc
    Las Vegas, Nevada 89128, United States
  • Virtua Health, Inc.
    Voorhees Township, New Jersey 08043, United States
  • Healthwise Medical Associates
    Brooklyn, New York 11206, United States
  • Trinity Medical Western New York, PC
    Cheektowaga, New York 14227, United States
  • WMCHealth Heart and Vascular Institute Kingston Division of Cardiology
    Kingston, New York 12401, United States
  • Northwell Health Physician Partners Cardiology
    Manhasset, New York 11030, United States
  • North Shore Diabetes and Endocrine Associates
    New Hyde Park, New York 11042, United States
  • Northwell Health Lenox Hill Heart and Vascular
    New York, New York 10022, United States
  • Hudson Valley Cardiovascular Physicians PC
    Poughkeepsie, New York 12601, United States
  • Saratoga Clinical Research, LLC
    Saratoga Springs, New York 12866, United States
  • Division of Cardiovascular Research at Peconic Bay Medical Center
    Southampton, New York 11968, United States
  • Asheville Cardiology Associates
    Asheville, North Carolina 28803, United States
  • University of North Carolina at Chapel Hill
    Chapel Hill, North Carolina 27599, United States
  • Novant Health Heart and Vascular Institute
    Charlotte, North Carolina 28204, United States
  • Moses H Cone Memorial Hospital
    Greensboro, North Carolina 27401, United States
  • Crossroads Clinical Research Inc
    Mooresville, North Carolina 28117, United States
  • Piedmont Medical Group Research of Rocky Mount
    Rocky Mount, North Carolina 27804, United States
  • PMG Research of Salisbury
    Salisbury, North Carolina 28144, United States

Showing the first 100 of 852 sites across 33 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Bohula EA, Marston NA, Ruzza A, Murphy SA, De Ferrari GM, Diaz R, Leiter LA, Elliott-Davey M, Wang H, Bhatia AK, Giugliano RP, Sabatine MS. Rationale and design of the effect of evolocumab in patients at high cardiovascular risk without prior myocardial infarction or stroke (VESALIUS-CV) trial. Am Heart J. 2024 Mar;269:179-190. doi: 10.1016/j.ahj.2023.12.004. Epub 2023 Dec 29. PubMed 38160917 ↗
  • Monguillon V, Marston NA, Bohula EA, Park JG, Kuder JF, Murphy SA, De Ferrari GM, Leiter LA, Nicolau JC, Ebenbichler C, Sinnaeve P, Goudev A, Budaj A, Averkov O, Tokgozoglu L, Blankstein R, Vinereanu D, Giugliano RP, Sabatine MS, O'Donoghue ML. Lipoprotein(a) Levels, Risk of Cardiovascular Events, and Benefit of Evolocumab: Findings From the VESALIUS-CV Trial. Circulation. 2026 Jun 23;153(25):1960-1968. doi: 10.1161/CIRCULATIONAHA.126.080999. Epub 2026 May 25. PubMed 42183757 ↗
  • Bergmark BA, Bohula EA, Marston NA, Park JG, Kuder JF, Murphy SA, De Ferrari G, Leiter LA, Nicolau JC, Averkov O, Charng MJ, Ebenbichler C, Erglis A, Gouni-Berthold I, Montalescot G, Nicholls SJ, Sigurdsson A, Sinnaeve PR, Slapikas R, Tsioufis K, Verma S, Viigimaa M, Bhatia A, Xin L, Walsh E, Ohman EM, Giugliano RP, Sabatine MS. Evolocumab in Patients With Prior Percutaneous Coronary Intervention and No Prior Myocardial Infarction: Results From the VESALIUS-CV Trial. Circulation. 2026 Jul 7;154(1):28-36. doi: 10.1161/CIRCULATIONAHA.126.080616. Epub 2026 May 19. PubMed 42153665 ↗
  • Marston NA, Bohula EA, Bhatia AK, De Ferrari GM, Leiter LA, Nicolau JC, Park JG, Murphy SA, Walsh E, Liu L, Verma S, Sattar N, Nicholls SJ, Lopez-Sendon J, Gouni-Berthold I, Tokgozoglu L, Blankstein R, Cyrille M, da Silva Lima GP, Giugliano RP, Sabatine MS; VESALIUS-CV Investigators. Evolocumab to Reduce First Major Cardiovascular Events in Patients Without Known Significant Atherosclerosis and With Diabetes: Results From the VESALIUS-CV Trial. JAMA. 2026 Apr 28;335(16):1400-1407. doi: 10.1001/jama.2026.3277. PubMed 41903215 ↗
  • Bohula EA, Marston NA, Bhatia AK, De Ferrari GM, Leiter LA, Nicolau JC, Park JG, Kuder JF, Murphy SA, Walsh E, Wang H, Blaha V, Budaj A, Cornel JH, Goudev A, Kiss RG, Lorenzatti AJ, Parkhomenko A, Cyrille M, Paiva da Silva Lima G, Ohman EM, Giugliano RP, Sabatine MS; VESALIUS-CV Investigators. Evolocumab in Patients without a Previous Myocardial Infarction or Stroke. N Engl J Med. 2026 Jan 8;394(2):117-127. doi: 10.1056/NEJMoa2514428. Epub 2025 Nov 8. PubMed 41211925 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) The product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the link below.

Data sharing details ↗ · www.amgen.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2019 to primary completion in Jul 2025, 73 months.

Results were first posted in Jun 2026, 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 11, 2019
First posted
Mar 13, 2019
StartActual
Jun 11, 2019
Primary completionActual
Jul 25, 2025
CompletionActual
Jul 25, 2025
Results first posted
Jun 25, 2026
Last update
Jun 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03872401
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Mar 13, 2019
Start date
Jun 11, 2019
Primary completion
Jul 25, 2025
Completion
Jul 25, 2025
Results posted
Jun 25, 2026
Last update
Jun 25, 2026

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Evolocumab

Start the discussion